Trump’s former surgeon general: One year in, the war on vaccination is undoing the Trump administration’s health agenda

HHS Secretary Robert F. Kennedy Jr. has implemented contentious policies including firing 17 ACIP experts, rescinding some vaccine recommendations, and canceling $500 million in mRNA contracts, raising regulatory and political risk for vaccine and biotech firms. Public-health metrics have worsened—kindergarten measles vaccination fell from ~95% pre-pandemic to ~92.5%, the U.S. recorded >1,900 measles cases in 2025 (including a West Texas outbreak with 3 deaths and >860 infections), and one-third of adults reported hearing false claims about measles vaccine safety—creating potential demand-side headwinds for immunization programs and implications for vaccine developers, insurers, and related healthcare investors.

Analysis

Market structure: Policy-driven vaccine hesitancy and $500M mRNA contract cancellations shift near-term demand away from high-margin mRNA specialists and toward diversified pharmas, traditional vaccine makers, and pediatric care services. Winners: large-cap diversified pharmas (PFE, MRK, GSK, SNY) and consumer staples able to reformulate (MDLZ, KHC); losers: high-beta mRNA pure-plays (MRNA, BNTX) and small-cap vaccine developers dependent on public contracts. Cross-asset: expect elevated implied vol in biotech equities (IV +20–40% vs. baseline) and risk-off flows into Treasuries/JPY and gold during outbreak headlines.

Risk assessment: Tail risks include major outbreaks triggering emergency procurement (+$1–3B episodic demand) or litigation/regulatory clampdowns on vaccine makers; political reversal (election or court) could restore contracts within 3–12 months. Immediate window (days–weeks) brings headline-driven spikes; short term (1–3 months) will see repricing as ACIP/FDA guidance clarifies; long term (2–5 years) persistent hesitancy could reduce childhood vaccine TAM by an estimated 5–15%. Hidden dependencies: reimbursement policies, school-mandate litigation, and state-level procurement create uneven regional demand.

Trade implications: Favor long positions in diversified pharma and short concentrated mRNA exposure; use 3-month option put spreads to hedge high-volatility names and buy call spreads on large pharmas ahead of Q3 flu contract awards. Rotate from small-cap biotech to staples/health insurers (short-term hedge) and size positions to 1–3% of portfolio per trade with 6–12 month horizons.

Contrarian angles: Consensus may overprice structural demand loss for vaccines—historical parallels (post-2009 H1N1) show restoration after outbreaks and policy reversals within 12–24 months, creating recovery upside for beaten-down mRNA names. Unintended consequence: more measles/flu outbreaks actually accelerate procurement of traditional vaccines and therapeutics, benefiting incumbents and quick-to-market generics; consider asymmetric long exposure to diversified vaccine franchises.

Key Decisions for Investors

• Establish a 2–3% long position in Pfizer (PFE) and Merck (MRK) combined (1–1 weighting) over the next 2–4 weeks to capture defensive vaccine and oncology cash flows; target 6–12 month hold and sell into any 15–25% rally.
• Reduce exposure to pure-play mRNA names (Moderna MRNA, BioNTech BNTX) by 50% within 30 days; hedge remaining exposure with 3-month put spreads (buy 1 25% OTM put / sell 1 40% OTM put) sized to cover at least 50% of notional.
• Implement a pair trade: long PFE (or GSK) vs short MRNA equal-dollar notional (size 1–2% portfolio) with 6–12 month horizon—thesis: diversified pharmas outperform mRNA under policy uncertainty.
• Add a 1–2% position in consumer staples with reformulation capacity (Mondelez MDLZ or Kraft Heinz KHC) within 4 weeks to capture demand shift from dye-removal and defensive consumption; target 6–12 month hold and trim on +10% move.